Pakistan Medicines & Pharma IntelligenceMedicine data  •  Company portfolios  •  Price records
MedInfoBaseMedicines · Evidence · Intelligence
Home / Pharmaceutical company intelligence
Pharmaceutical company intelligence

Well & Well Pharma Pvt.Ltd

Pharmaceutical manufacturer · Pakistan

Database-driven profile Portfolio, price and regulatory-source intelligence derived from MedInfoBase records.
ShareSend this page
Regulatory & corporate identity

Company profile

Not yet verified
Company type
Pharmaceutical manufacturer
DRAP-linked licence identifiersShown as recorded in linked source rows; not a claim of current validity.
DML 000687 59 linked products · source seen 10 Aug 2026 View source ↗
Location intelligence

Company location

Google Maps
Exact site not yet verified

MedInfoBase will not invent a factory or office location. The map appears after a sourced address, Place ID or verified embed URL is added.

Open in Google Maps ↗ The Google Maps search link uses the company name and available city/country context; it is not presented as a verified premises pin.
Intelligence snapshot

Portfolio at a glance

Not sales data · current MedInfoBase database view
Rx59product presentations
G24generic molecules
DF6dosage-form groups
TA7therapeutic areas
PKR59current price records
REG53registration numbers
Data coverage

How complete is this profile?

Current price coverage100%
products with a current official price
Source-linked coverage100%
products linked back to a source record
Unit-price parse coverage98%
priced packs safely normalized per unit
Comparable-market coverage95%
products with at least one like-for-like comparator
Therapeutic classification100%
products assigned to a broad therapeutic area
Visual intelligence

Downloadable company intelligence charts

Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.

Shareable intelligence

Therapeutic Portfolio Mix

Shows where the company portfolio is concentrated across broad therapeutic areas.

Therapeutic Portfolio MixWell & Well Pharma Pvt.LtdShare of current product presentations by broad therapeutic areaMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/well-well-pharma-pvt-ltdGenerated 10 Aug 2026Anti-infectives46 · 78%Gastrointestinal & hepatology5 · 8%Cardiovascular3 · 5%Vitamins, minerals & nutrition2 · 3%Hematology & thrombosis1 · 2%Fluids & supportive care1 · 2%Pain & musculoskeletal1 · 2%Percentages are based on current product presentations in the MedInfoBase company portfolio.

Portfolio distribution, not sales or market-share data.

Shareable intelligence

Dosage Form Portfolio

Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.

Dosage Form PortfolioWell & Well Pharma Pvt.LtdDistribution of current product presentations by normalized dosage formMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/well-well-pharma-pvt-ltdGenerated 10 Aug 202659presentationsTablet21 · 36%Injection12 · 20%Capsule11 · 19%Suspension11 · 19%Infusion3 · 5%Sachet1 · 2%Dosage-form wording is normalized for intelligence display; original source wording remains preserved in product records.

Counts are product presentations, not production or sales volumes.

Shareable intelligence

Equivalent-Market Price Position

Shows whether safely comparable products are below, near or above the market median unit price.

Equivalent-Market Price PositionWell & Well Pharma Pvt.LtdCurrent company products compared with like-for-like equivalent medicines using normalized unit pricesMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/well-well-pharma-pvt-ltdGenerated 10 Aug 202656comparable productsBelow market median10 · 18%Near market median42 · 75%Above market median4 · 7%Company median price position-0.4%Lowest-price equivalents6Method: same generic + stated strength + dosage form + compatible unit basis; pack prices normalized per unit.

This is price-position intelligence, not sales, demand or market-share data.

Shareable intelligence

Closest Portfolio Competitors

Highlights other manufacturers with the greatest generic overlap with this company portfolio.

Closest Portfolio CompetitorsWell & Well Pharma Pvt.LtdCompanies with the largest number of shared generic medicines in the MedInfoBase databaseMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/well-well-pharma-pvt-ltdGenerated 10 Aug 2026M/s. Genix Pharma (Pvt) Ltd.19 shared79% overlapSAMI Pharmaceuticals Pvt. Ltd.19 shared79% overlapPharmasol (Pvt) Ltd.18 shared75% overlapMacter International Limited18 shared75% overlapMediate Pharmaceutical Pvt Ltd18 shared75% overlapNeutro Pharma (Pvt.) Ltd.,18 shared75% overlapPortfolio overlap measures shared generics only; it is not a measure of market share, affiliation or sales competition.

Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.

Portfolio intelligence

Therapeutic areas

Broad portfolio view

High-level clinical areas represented by this company’s current MedInfoBase portfolio.

Anti-infectives46 products · 78%
Gastrointestinal & hepatology5 products · 8%
Cardiovascular3 products · 5%
Vitamins, minerals & nutrition2 products · 3%
Hematology & thrombosis1 products · 2%
Fluids & supportive care1 products · 2%
Pain & musculoskeletal1 products · 2%
Pharmacological detail

Drug classes

More specific view

More specific classes derived from the canonical generic and preserved curated classifications.

Third-generation cephalosporins12 products · 20%
Macrolide antibacterials11 products · 19%
Fluoroquinolone antibacterials9 products · 15%
Proton pump inhibitors5 products · 8%
First-generation cephalosporins4 products · 7%
Antifungals4 products · 7%
Antimalarials4 products · 7%
Beta blockers3 products · 5%
Formulation footprint

Dosage forms

Tablet21 products
Injection12 products
Capsule11 products
Suspension11 products
Infusion3 products
Sachet1 products
How MedInfoBase classifies the portfolio

MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.

Portfolio leaders

Deepest brand families

Ranked by registered presentations · not sales
#1 ZithrovelAzithromycin 7presentations 200 mg/5 mL, 250 mg, 500 mg · Suspension, Capsule, Tablet #2 CipnoloneCiprofloxacin 6presentations 125 mg/5 mL, 200 mg/100 mL, 250 mg, 250 mg/5 mL · Suspension, Injection, Tablet #3 CalssicaCeftriaxone 5presentations 1 g, 250 mg, 500 mg · Injection #4 CephzinCephalexin 4presentations 125 mg/5 mL, 250 mg, 250 mg/5 mL, 500 mg · Suspension, Capsule #5 BisovelBisoprolol fumarate 3presentations 10 mg, 2.5 mg, 5 mg · Tablet #6 CefivelCefixime 3presentations 100 mg/5 mL, 200 mg/5 mL, 400 mg · Suspension, Capsule
Price intelligence

Unit-price positioning vs equivalent products

Same generic + strength + form + unit basis
Below market median1018% of comparable products
Near market median42within ±5% of median
Above market median47% of comparable products
Lowest-price equivalents6ties included
Company median price position -0.4% relative to the median unit price of like-for-like equivalent products.
Most competitively positioned examplesProducts with at least 3 market comparators
Tracowel 100 mgItraconazole · Capsule · 1x4`s PKR 93.35/capsule-35.1% vs market median Malavel 80 mg + 480 mgArtemether + Lumefantrine · Tablet · 6`s PKR 73.25/tablet-32.8% vs market median Zithrovel 250 mgAzithromycin · Tablet · 1x10's PKR 36.37/tablet-22.4% vs market median Zithrovel 500 mgAzithromycin · Tablet · 1x10's PKR 66.67/tablet-21.4% vs market median Cipnolone 125 mg/5 mLCiprofloxacin · Suspension · 60ml PKR 2.83/mL-19.9% vs market median
How MedInfoBase calculates price position

Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.

Competitive landscape

Portfolio overlap

Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.

M/s. Genix Pharma (Pvt) Ltd.290 products · 97 generics 19shared generics SAMI Pharmaceuticals Pvt. Ltd.188 products · 64 generics 19shared generics Pharmasol (Pvt) Ltd.251 products · 101 generics 18shared generics Macter International Limited248 products · 91 generics 18shared generics Mediate Pharmaceutical Pvt Ltd239 products · 90 generics 18shared generics Neutro Pharma (Pvt.) Ltd.,210 products · 97 generics 18shared generics
Regulatory & price activity

Observed database signals

Registration numbers53
Price-history records64
Products with price history5
Source records with multiple versions0
Latest MedInfoBase verification9 Aug 2026
Latest effective price date27 Jul 2026
Latest source observation10 Aug 2026

These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.

Sponsored company campaign area · advertising must be clearly disclosed
Complete company portfolio

Products and presentations

59 results
Reset
BrandGenericStrengthFormPackRegistrationOfficial priceUnit priceMarket position
Bisovel Bisoprolol fumarate 2.5 mg Tablet 14's 095339 PKR 55.39 PKR 3.96/tablet 7% below median
Bisovel Bisoprolol fumarate 5 mg Tablet 2x10's 095340 PKR 230.82 PKR 11.54/tablet Near median
Bisovel Bisoprolol fumarate 10 mg Tablet 2x10's 095338 PKR 415.49 PKR 20.77/tablet 6% below median
Calssica Ceftriaxone 250 mg Powder for injection 1's 098388 PKR 186.50 PKR 186.50/vial/unit Near median
Calssica Ceftriaxone 500 mg IM injection 1's 098389 PKR 313.92 PKR 313.92/vial/unit Near median
Calssica Ceftriaxone 500 mg IV injection 1's 098386 PKR 313.92 PKR 313.92/vial/unit Near median
Calssica Ceftriaxone 250 mg Powder for injection 1's 098385 PKR 186.50 PKR 186.50/vial/unit Near median
Calssica Ceftriaxone 1 g Powder for injection 1's 098387 PKR 592.76 PKR 592.76/vial/unit Near median
Carezole Metronidazole (Benzoate) 500 mg/100 mL IV infusion 100ml 119034 PKR 155.59 PKR 1.56/mL 14% below median
Cefivel Cefixime 400 mg Capsule 5's 085326 PKR 563.10 PKR 112.62/capsule Near median
Cefivel Cefixime 200 mg/5 mL Dry suspension 30ml 085324 PKR 384.55 PKR 12.82/mL Near median
Cefivel Cefixime 100 mg/5 mL Dry suspension 30ml 085325 PKR 314.24 PKR 10.47/mL Near median
Cefravel Cefoperazone 1 g Powder for injection 1's 097539 PKR 415.49 PKR 415.49/vial/unit No comparator
Cephzin Cephalexin 250 mg Capsule 12's 093325 PKR 188.36 PKR 15.70/capsule Near median
Cephzin Cephalexin 500 mg Capsule 12's 093324 PKR 369.31 PKR 30.78/capsule Near median
Cephzin Cephalexin 125 mg/5 mL Dry suspension 60ml 093334 PKR 108.94 PKR 1.82/mL Near median
Cephzin Cephalexin 250 mg/5 mL Dry suspension 60ml 093333 PKR 188.36 PKR 3.14/mL Near median
Cipnolone Ciprofloxacin 250 mg/5 mL Suspension 60ml 070067 PKR 304.05 PKR 5.07/mL Near median
Cipnolone Ciprofloxacin 250 mg Tablet 10's 065127 PKR 247.05 PKR 24.71/tablet Near median
Cipnolone Ciprofloxacin 500 mg Tablet 10's 065128 PKR 408.58 PKR 40.86/tablet Near median
MedInfoBase company-intelligence methodology

This page is generated from MedInfoBase medicine, generic, company, price and DRAP-source records. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.

Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.